Matinas BioPharma Holdings Inc Share Price Other OTC
Equities
US5768101058
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-09 | Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 42.01M 3.31B |
---|---|---|---|---|---|
Net income 2024 * | -25M -1.97B | Net income 2025 * | -34M -2.68B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.68
x | P/E ratio 2025 * |
-1.52
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.47% |
Latest transcript on Matinas BioPharma Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Jerome Jabbour
FOU | Founder | 50 | 30/04/13 |
Keith Kucinski
DFI | Director of Finance/CFO | 55 | 02/01/19 |
Hui Liu
CTO | Chief Tech/Sci/R&D Officer | 56 | 30/11/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Herbert Conrad
FOU | Founder | 91 | 30/04/13 |
Natasha Giordano
BRD | Director/Board Member | 62 | 13/09/20 |
Eric Ende
CHM | Chairman | 55 | 02/04/17 |
1st Jan change | Capi. | |
---|---|---|
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |